Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.
WHY is this medicine prescribed?
Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes. temsirolimustemsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. temsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
What should I know about Addyi before using it?
teniposideteniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. teniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosteronetestosterone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosterone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosterone topical will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Pediatric Precautions
tranylcyprominetranylcypromine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tranylcypromine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. trazodonetrazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. trazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. triclabendazoletriclabendazole will increase the level or effect of flibanserin by affecting hepatic bayer vardenafil enzyme CYP2C19 metabolism. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes. temsirolimustemsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. temsirolimus will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Flibanserin was developed by Boehringer Ingelheim, later licensed to Sprout Pharmaceuticals.
- It is considered a "female Viagra," though its mechanism differs from male erectile drugs.
- The medication is part of the growing field of female sexual dysfunction treatment.
- Most clinical trials showed a modest increase in satisfying sexual events.
- Flibanserin should be taken consistently for best results.
- It is not recommended for women who are pregnant or breastfeeding.
- Common adverse reactions include dry mouth and insomnia.
- The drug was approved after extensive clinical trials involving thousands of women.
- Long-term safety data is still being collected.
teniposideteniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. teniposide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosteronetestosterone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Apcalis SX Oral Jelly | 20mg | 120 + 13 Sachets | 280.38€ 267.03€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Levitra Generic | 20mg | 120 + 10 Pills | 224.15€ 213.48€ | |
| Cialis Professional | 40mg | 120 + 4 Pills | 436.68€ 415.89€ | |
| Levitra Professional | 20mg | 20 Pills | 101.00€ 96.19€ | |
| Cialis Generic | 10mg | 90 + 6 Pills | 146.17€ 139.21€ | |
| Levitra Generic | 20mg | 60 + 6 Pills | 131.11€ 124.87€ | |
| Viagra Oral Jelly | 100mg | 110 + 9 Sachets | 284.63€ 271.08€ | |
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ | |
| Priligy Generic Dapoxetine | 60mg | 20 + 4 Pills | 77.31€ 73.63€ | |
| Cialis Generic | 60mg | 60 + 4 Pills | 145.06€ 138.15€ | |
| Levitra Generic | 40mg | 270 + 10 Pills | 561.89€ 535.13€ |
testosterone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. testosterone topical will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- The prescribing guidelines emphasize cautious use in women on other psychotropic drugs.
- Flibanserin's approval was driven by a need for female-specific sexual health medications.
- Its mechanism involves serotonergic pathways impacting sexual response.
- The drug is typically part of a broader therapy including counseling or therapy.
- Studies indicate a small but statistically significant benefit for some women.
- It is important to rule out other medical or psychological causes before use.
- Flibanserin is contraindicated with certain medications, such as CYP3A4 inhibitors.
- Side effect management includes monitoring blood pressure and mental status.
- The medication's role is to improve quality of life by addressing sexual desire challenges.
tranylcyprominetranylcypromine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tranylcypromine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. trazodonetrazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. trazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. triclabendazoletriclabendazole will increase the level or effect of flibanserin by affecting hepatic bayer vardenafil enzyme CYP2C19 metabolism. If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole.
Related/similar drugs
Dosage Forms & Strengths
triclabendazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.
Other uses for this medicine
If plasma concentrations of the CYP2C19 substrates are elevated during triclabendazole, recheck plasma concentration of the CYP2C19 substrates after discontinuation of triclabendazole. triclabendazole will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. valproic acidvalproic acid will increase the level or effect cenforce 150 uk of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.valproic acid and flibanserin both increase sedation. valproic acid will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Does Addyi interact with foods or drinks?
vinblastinevinblastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinblastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristinevincristine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristine liposomal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Interaction with Alcohol
vinorelbinevinorelbine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinorelbine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. zafirlukastzafirlukast will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. zafirlukast will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ziprasidoneziprasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. valproic acidvalproic acid will increase the level or effect cenforce 150 uk of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.valproic acid and flibanserin both increase sedation.
if she’s saying these things, it may be hsdd
Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, ziprasidone. ziprasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamideacetazolamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. anastrozoleanastrozole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Dosage forms and strengths (USA)
anastrozole will increase the level or effect of flibanserin by affecting premature ejaculation medicine hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamidecyclophosphamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenonedrospirenone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Related Pages
Coadministration of flibanserin and alcohol close in time increases risk of severe hypotension and syncope Counsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 standard alcoholic drinks were consumed that evening Coadministration with moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope Therefore, use of moderate or strong CYP3A4 inhibitors is contraindicated Contraindicated for use with any degree of hepatic impairment Flibanserin exposure increased 4.5-fold in patients with hepatic impairment, compared with those with normal hepatic function, increasing the risk of hypotension and syncope Coadministration with moderate or strong CYP3A4 inhibitors Hypersensitivity reactions, including anaphylaxis, reactions consistent with angioedema (eg, swelling of the face, lips, and mouth), pruritus, and urticaria reported Coadministration within 2 hr of consuming alcohol increases risk of severe hypotension and syncope (see Black Box Warnings) Hypotension and syncope can also occur with flibanserin taken alone; because of this risk, instruct patient to take at bedtime Patients who drink >3 standard alcoholic drinks should skip their dose that evening; 1 standard alcoholic drink contains 14 grams of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol); after takingflibanserin, patients should not use alcohol until the following day Use in patients with hepatic impairment is contraindicated; hepatic impairment significantly increases flibanserin concentrations, which can lead to hypotension and syncope Malignant mammary tumors in female mice were observed at exposures 3 and 10 times the recommended clinical dose; no increases were seen in male mice or in male or female rats; clinical significance of this observations is unknown AlcoholCounsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 alcoholic drinks were consumed that eveningAlcohol potentiates toxicities of flibanserin the risk of hypotension, syncope, and CNS depression Counsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 alcoholic drinks were consumed that evening Alcohol potentiates toxicities of flibanserin the risk of hypotension, syncope, and CNS depression CNS depressantsMonitor and consultCoadministration with other drugs that also cause CNS depression may increase risk of somnolence, sedation, or fatiguePatients should not drive or do other activites requiring full alertness for at least 6 hr after taking flibanserin until they know how the drug affects them Coadministration with other drugs that also cause CNS depression may increase risk of somnolence, sedation, or fatigue Patients should not drive or do other activites requiring full alertness for at least 6 hr after taking flibanserin until they know how the drug affects them Moderate or strong CYP3A4 inhibitorsContraindicatedModerate or strong CYP3A4 inhibitors increases flibanserin exposure, which increases risk of hypotension and syncope Moderate or strong CYP3A4 inhibitors increases flibanserin exposure, which increases risk of hypotension and syncope Weak CYP3A4 inhibitorsMonitor and consultMultiple weak CYP3A4 inhibitors may increase risk of adverse reactions of flibanserin Multiple weak CYP3A4 inhibitors may increase risk of adverse reactions of flibanserin Strong CYP2C19 inhibitorsMonitorStrong CYP2C19 inhibitors may increase flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression Strong CYP2C19 inhibitors may increase flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression CYP3A4 inducersNot recommendedCYP3A4 inducers substantially decrease flibanserin exposure Digoxin or other P-glycoprotein substratesMonitorClosely monitor P-gp substrates with a narrow therapeutic index (eg, digoxin)Flibanserin increases digoxin concentration, which may lead to digoxin toxicity Closely monitor P-gp substrates with a narrow therapeutic index (eg, digoxin) Flibanserin increases digoxin concentration, which may lead to digoxin toxicity There are no studies in pregnant women to inform whether there is a drug-associated risk in humans In animals, fetal toxicity only occurred in the presence of significant maternal toxicity, including reductions in weight gain and sedation Adverse reproductive and developmental effects consisted of decreased fetal weight, structural anomalies, and increases in fetal loss at exposures greater than 15 times exposures achieved with the recommended human dosage Unknown if distributed in human breast milk Unknown whether flibanserin has effects on the breastfed infant or if it affects milk production Because of the potential for serious adverse reactions, including sedation, in a breastfed infant, breastfeeding is not recommended during treatment Controlled studies in pregnant women show no evidence of fetal risk. valproic acid will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinblastinevinblastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinblastine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristinevincristine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vincristine liposomal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinorelbinevinorelbine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. vinorelbine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Issue | Description |
|---|---|
| Efficacy Debate | Some experts question the clinical significance of benefits |
| Side Effect Concerns | Risks of hypotension, syncope, and severe allergic reactions |
| Marketing & Approval Controversies | Criticism over FDA approval process and marketing practices |
| Post-Marketing Surveillance | Ongoing monitoring for rare adverse events |
zafirlukastzafirlukast will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. zafirlukast will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ziprasidoneziprasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, ziprasidone.
| Parameter | Description | Typical Values |
|---|---|---|
| Absorption | Rapid, high bioavailability | ~52% |
| Peak Plasma Levels | 1-2 hours after dosing | ~1.5 hours |
| Half-life | Duration of effect | 11 hours |
| Metabolism | Hepatic via CYP3A4 | Major route |
| Excretion | Mainly via urine | 87% in urine |
ziprasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamideacetazolamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. anastrozoleanastrozole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Flibanserin is classified as a centrally acting serotonergic agent.
- It is not a testosterone-based therapy, unlike some other treatments.
- The FDA approval was based on studies showing increased sexual desire in women.
- The medication can cause sleep disturbances, including somnolence.
- Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
- It is recommended to start treatment at least 4 weeks before expecting improvement.
- Discontinuation of the drug normally leads to the loss of effects.
- The drug's efficacy is modest compared to some male sexual dysfunction drugs.
- Initiation of therapy involves screening for contraindications.
anastrozole will increase the level or effect of flibanserin by affecting premature ejaculation medicine hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamidecyclophosphamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Potential for negative publicity and stigma surrounding a "pink Viagra."
- Media coverage often oversimplifies its mechanism and expected results.
- Patient education is crucial to set realistic expectations about benefits.
- Support groups and online communities exist for women discussing HSDD treatment.
- Ongoing research continues to explore other pharmacologic targets for HSDD.
- Future developments may include new formulations or combination therapies.
- The approval of flibanserin spurred increased investment in female sexual health.
- It remains a subject of debate in medical ethics, women's health, and drug regulation.
- Prescribers should stay updated on post-marketing safety communications.
drospirenonedrospirenone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of flibanserin and alcohol close in time increases risk of severe hypotension and syncope Counsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 standard alcoholic drinks were consumed that evening Coadministration with moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope Therefore, use of moderate or strong CYP3A4 inhibitors is contraindicated Contraindicated for use with any degree of hepatic impairment Flibanserin exposure increased 4.5-fold in patients with hepatic impairment, compared with those with normal hepatic function, increasing the risk of hypotension and syncope Coadministration with moderate or strong CYP3A4 inhibitors Hypersensitivity reactions, including anaphylaxis, reactions consistent with angioedema (eg, swelling of the face, lips, and mouth), pruritus, and urticaria reported Coadministration within 2 hr of consuming alcohol increases risk of severe hypotension and syncope (see Black Box Warnings) Hypotension and syncope can also occur with flibanserin taken alone; because of this risk, instruct patient to take at bedtime Patients who drink >3 standard alcoholic drinks should skip their dose that evening; 1 standard alcoholic drink contains 14 grams of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol); after takingflibanserin, patients should not use alcohol until the following day Use in patients with hepatic impairment is contraindicated; hepatic impairment significantly increases flibanserin concentrations, which can lead to hypotension and syncope Malignant mammary tumors in female mice were observed at exposures 3 and 10 times the recommended clinical dose; no increases were seen in male mice or in male or female rats; clinical significance of this observations is unknown AlcoholCounsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 alcoholic drinks were consumed that eveningAlcohol potentiates toxicities of flibanserin the risk of hypotension, syncope, and CNS depression Counsel patients to wait at least 2 hr after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip flibanserin dose if ≥3 alcoholic drinks were consumed that evening Alcohol potentiates toxicities of flibanserin the risk of hypotension, syncope, and CNS depression CNS depressantsMonitor and consultCoadministration with other drugs that also cause CNS depression may increase risk of somnolence, sedation, or fatiguePatients should not drive or do other activites requiring full alertness for at least 6 hr after taking flibanserin until they know how the drug affects them Coadministration with other drugs that also cause CNS depression may increase risk of somnolence, sedation, or fatigue Patients should not drive or do other activites requiring full alertness for at least 6 hr after taking flibanserin until they know how the drug affects them Moderate or strong CYP3A4 inhibitorsContraindicatedModerate or strong CYP3A4 inhibitors increases flibanserin exposure, which increases risk of hypotension and syncope Moderate or strong CYP3A4 inhibitors increases flibanserin exposure, which increases risk of hypotension and syncope Weak CYP3A4 inhibitorsMonitor and consultMultiple weak CYP3A4 inhibitors may increase risk of adverse reactions of flibanserin Multiple weak CYP3A4 inhibitors may increase risk of adverse reactions of flibanserin Strong CYP2C19 inhibitorsMonitorStrong CYP2C19 inhibitors may increase flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression Strong CYP2C19 inhibitors may increase flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression CYP3A4 inducersNot recommendedCYP3A4 inducers substantially decrease flibanserin exposure Digoxin or other P-glycoprotein substratesMonitorClosely monitor P-gp substrates with a narrow therapeutic index (eg, digoxin)Flibanserin increases digoxin concentration, which may lead to digoxin toxicity Closely monitor P-gp substrates with a narrow therapeutic index (eg, digoxin) Flibanserin increases digoxin concentration, which may lead to digoxin toxicity There are no studies in pregnant women to inform whether there is a drug-associated risk in humans In animals, fetal toxicity only occurred in the presence of significant maternal toxicity, including reductions in weight gain and sedation Adverse reproductive and developmental effects consisted of decreased fetal weight, structural anomalies, and increases in fetal loss at exposures greater than 15 times exposures achieved with the recommended human dosage Unknown if distributed in human breast milk Unknown whether flibanserin has effects on the breastfed infant or if it affects milk production Because of the potential for serious adverse reactions, including sedation, in a breastfed infant, breastfeeding is not recommended during treatment Controlled studies in pregnant women show no evidence of fetal risk.
| Aspect | Details |
|---|---|
| Chemical Formula | C_20H_21F_3N_4O |
| Molecular Weight | 370.41 g/mol |
| Key Functional Groups | Triazole ring, fluorinated phenyl group |
| Structural Type | Non-steroidal compound |